☆ 4.4 Review

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

NEUROLOGY AND THERAPY (2023)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: A pairwise and network meta-analysis of randomized controlled trials

Aqeeb Ur Rehman et al.

Summary: This meta-analysis examines the efficacy and safety of tenecteplase at different doses. It found that a dose of 0.25 mg/kg significantly improved functional and neurological outcomes at 3 months. There were no significant differences between tenecteplase and alteplase in terms of good functional outcomes, intracerebral hemorrhage, symptomatic intracerebral hemorrhage, and 90-day mortality. Meta-regression analysis showed a potential advantage of tenecteplase with increasing stroke severity, but the results were not statistically significant.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials

Mohamed Abuelazm et al.

Summary: This study evaluated the safety and efficacy of Tenecteplase versus alteplase in acute ischemic stroke (AIS) and investigated the optimal dosage of Tenecteplase. The results showed that Tenecteplase significantly improved complete recanalization, but did not differ from alteplase in terms of early neurological improvement and excellent neurological recovery. There were no significant differences between Tenecteplase and alteplase in terms of mortality, intracranial haemorrhage, and parenchymal hematoma. The dosage of 0.25 mg of Tenecteplase could be a viable option for standard care in AIS patients presenting within 4.5 hours.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2023)

Add to Collection

Article Clinical Neurology

Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis

Vignan Yogendrakumar et al.

Summary: This study assessed the reperfusion efficacy of tenecteplase and alteplase in different subgroups based on thrombus characteristics. The results showed that tenecteplase was more effective in achieving early reperfusion in lesions with low clot burden compared to alteplase. However, both thrombolytics had limited efficacy in internal carotid artery occlusions and lesions with high clot burden.

STROKE (2023)

Add to Collection

Review Clinical Neurology

Replacing Alteplase with Tenecteplase Is the Time Ripe

Nishita Singh et al.

Summary: This review focuses on recent advances in thrombolysis for acute ischemic stroke, comparing alteplase and TNK in terms of clinical, imaging, and safety outcomes. It highlights the potential of TNK as an alternative choice, with similar efficacy and safety as alteplase. Further research is needed to determine the advantages and applications of TNK in different subgroups.

JOURNAL OF STROKE (2023)

Add to Collection

Article Medicine, General & Internal

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferioritytrial

Yongjun Wang et al.

Summary: This study aimed to compare the thrombolytic treatment effect of alteplase and tenecteplase in patients with acute ischaemic stroke. The results showed that tenecteplase was non-inferior to alteplase in achieving a modified Rankin Scale score of 0-1 at 90 days, and the safety profiles of both drugs were similar.

LANCET (2023)

Add to Collection

Review Public, Environmental & Occupational Health

Prevalence of hypertension among type 2 diabetes mellitus patients in Ethiopia: a systematic review and meta-analysis

Teklehaimanot Gereziher Haile et al.

Summary: This study aimed to estimate the prevalence of hypertension among diabetic patients in Ethiopia. The results showed a high prevalence of hypertension among type 2 diabetes mellitus (DM) patients in Ethiopia, with a higher prevalence among urban residents. Appropriate preventive measures should be implemented to reduce the burden of hypertension among DM patients in Ethiopia.

INTERNATIONAL HEALTH (2023)

Add to Collection

Review Clinical Neurology

Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Deborah Rose et al.

Summary: This study compared the risk of treatment complications between intravenous tenecteplase and alteplase in acute ischemic stroke. It found that the risks of complications were generally comparable between the two agents in medium- and low-dose tiers.

STROKE (2023)

Add to Collection

Review Clinical Neurology

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials

Huo Liang et al.

Summary: This study compared the efficacy and safety of tenecteplase and alteplase for acute ischemic stroke. The results showed that both tenecteplase 0.25 mg/kg and alteplase 0.9 mg/kg were superior to placebo in improving functional outcomes. Moreover, tenecteplase 0.25 mg/kg outperformed alteplase 0.9 mg/kg in excellent functional outcome. Therefore, tenecteplase 0.25 mg/kg may be a better alternative to alteplase 0.9 mg/kg for acute ischemic stroke treatment.

FRONTIERS IN NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke

Mingfeng Zhai et al.

Summary: This study investigated the long-term prognostic effects of different alteplase doses on patients with acute ischemic stroke (AIS). The results showed that standard-dose alteplase treatment significantly reduced the risk of long-term recurrence of AIS, while alteplase dose was not associated with the risk of death from AIS.

NEUROLOGY AND THERAPY (2023)

Add to Collection

Article Clinical Neurology

Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial

Andrew Bivard et al.

Summary: The use of tenecteplase in a mobile stroke unit in Melbourne, Australia resulted in superior reperfusion compared to alteplase upon hospital arrival, with no safety concerns.

LANCET NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial

Christopher Elnan Kvistad et al.

Summary: This prematurely terminated study showed that 0.4 mg/kg tenecteplase yielded worse safety and functional outcomes compared to alteplase in patients with moderate and severe ischemic stroke.

LANCET NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study

Shuya Li et al.

Summary: This study compared the safety of different doses of rhTNK-tPA with standard rt-PA in Chinese AIS patients, showing that rhTNK-tPA administered within 3 hours of symptom onset was well tolerated at all doses. Further investigations are needed to establish the dose-efficacy profile of rhTNK-tPA.

STROKE AND VASCULAR NEUROLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke A Systematic Review and Meta-analysis

Aristeidis H. Katsanos et al.

Summary: Evidence from nonrandomized studies suggests that tenecteplase is as safe as alteplase and potentially associated with improved functional outcomes compared with alteplase.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Clinical Neurology

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?

Ammad Mahmood et al.

Summary: A single thrombolytic agent for all indications in acute ischaemic stroke is desirable to streamline workflows. Based on recent and upcoming trials, guidelines may soon recommend tenecteplase as a suitable alternative to alteplase. The use of tenecteplase in specific subgroups will depend on further recruitment to ongoing clinical trials.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2022)

Add to Collection

Review Clinical Neurology

Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis

Pengju Ma et al.

Summary: This systematic review and meta-analysis compared the efficacy and safety of tenecteplase with alteplase for the treatment of acute ischemic stroke (AIS) patients. The results showed no significant difference between the two drugs in terms of good outcome and excellent outcome at 90 days. However, patients receiving tenecteplase might have a higher incidence of early neurologic improvement compared to those receiving alteplase.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Editorial Material Medicine, General & Internal

What is the right drug for insomnia disorder?

Myrto T. Samara

LANCET (2022)

Add to Collection

Review Medicine, General & Internal

Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis

Xuemei Xiang et al.

Summary: This study aims to evaluate the predictive value of tumour mutation burden (TMB) in the efficacy of immune checkpoint inhibitors (ICIs). The study will compare the efficacy of ICIs between patients with high TMB and low TMB, and assess their impact on overall survival, progression-free survival, and objective response rate. Subgroup analysis, sensitivity analysis, heterogeneity analysis, and publication bias will also be conducted.

BMJ OPEN (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Risk of cardiovascular disease among cancer survivors: Protocol of a pooled analysis of population-based cohort studies

Botao Yu et al.

Summary: Cancer and cardiovascular disease share common risk factors and pose a burden on public health. This study aims to examine the association between cancer and subsequent cardiovascular disease risk through a meta-analysis. The analysis will follow strict guidelines for literature screening, data extraction, and statistical analysis.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice

Steven J. Warach et al.

Summary: Switching to tenecteplase as the standard thrombolytic treatment for stroke in a regional network of 10 hospitals resulted in reduced workflow times, noninferior clinical outcomes, and reduced hospital costs.

STROKE (2022)

Add to Collection

Review Hematology

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review

Annie Zhu et al.

Summary: This review compares Tenecteplase (TNK) and tissue plasminogen activator (tPA) in the treatment of acute ischemic stroke, outlining their indications, dosages, mechanisms of action, efficacy, and safety. It summarizes current clinical trial results and acute stroke treatment guidelines, providing treatment algorithms for managing the two main complications of intravenous thrombolysis.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Clinical Neurology

Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion

Fana Alemseged et al.

Summary: The study showed that the use of TNK prior to EVT in patients with BAO may lead to higher rates of reperfusion compared to alteplase. Randomized controlled trials comparing TNK with alteplase in BAO patients are needed to further validate these findings.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019

Valery L. Feigin et al.

Summary: Regularly updated data on stroke including incidence, prevalence, mortality, disability, risk factors, and trends are crucial for evidence-based care planning. The Global Burden of Diseases Study provides comprehensive measurement of these metrics. From 1990 to 2019, while age-standardized rates improved, the number of strokes and deaths increased. Low-income countries had the highest stroke-related mortality and DALY rates, with high body-mass index being the fastest-growing risk factor.

LANCET NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke

Cathy S. Zhong et al.

Summary: The routine use of tenecteplase for stroke thrombolysis is feasible and has comparable safety profile and outcomes to alteplase.

STROKE (2021)

Add to Collection

Review Emergency Medicine

Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis

M. Oliveira et al.

Summary: Tenecteplase, a genetically modified form of alteplase, showed higher rates of recanalization and early neurological improvement in adult patients with acute ischemic stroke undergoing thrombolysis. However, there were no significant differences between tenecteplase and alteplase in terms of functional outcome, intracerebral hemorrhage, symptomatic intracerebral hemorrhage, and mortality.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Plasminogen Activators in Neurovascular and Neurodegenerative Disorders

Manuel Yepes et al.

Summary: The neurovascular unit is a complex structure involving various cells and components that are essential for maintaining normal neuronal function. Plasminogen activators play a crucial role in regulating the function of the neurovascular unit, with dysfunction leading to neurodegenerative disorders. Research on the expression and function of tissue-type plasminogen activator and urokinase-type plasminogen activator in the neurovascular unit has provided valuable insights into neurovascular and neurodegenerative disorders.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings.

Minu George et al.

Summary: This study investigated the health outcomes of thrombolysis in patients with acute ischemic stroke in India, finding that Tenecteplase has similar clinical outcomes to Alteplase for stroke thrombolysis. The results suggest that Tenecteplase may be a better option for the management of acute ischemic stroke due to its relatively low-cost and ease of administration.

JOURNAL OF CLINICAL NEUROSCIENCE (2021)

Add to Collection

Article Clinical Neurology

Switching to Tenecteplase for Stroke Thrombolysis Real-World Experience and Outcomes in a Regional Stroke Network

Karim Mahawish et al.

Summary: The switch from alteplase to tenecteplase for stroke thrombolysis was successfully implemented with stakeholder endorsement. Patients treated with tenecteplase showed better clinical outcomes, shorter door-to-needle time, and similar complication rates compared to alteplase.

STROKE (2021)

Add to Collection

Article Clinical Neurology

Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion

Klearchos Psychogios et al.

Summary: The study compared the safety and efficacy of intravenous tenecteplase with alteplase in AIS patients with LVO. While early neurological improvement was slightly better in the tenecteplase group, there were no significant differences in other outcomes between the two groups, highlighting the need for further research confirmation.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke The EXTEND-IA TNK Part 2 Randomized Clinical Trial

Bruce C. V. Campbell et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Clinical Neurology

Tenecteplase Thrombolysis for Acute Ischemic Stroke

Steven J. Warach et al.

STROKE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Disease and Stroke Statistics-2019 Update A Report From the American Heart Association

Emelia J. Benjamin et al.

CIRCULATION (2019)

Add to Collection

Article Clinical Neurology

In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA

Tobias Fruehwald et al.

BMC NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials

Adrian M. Burgos et al.

STROKE (2019)

Add to Collection

Article Clinical Neurology

Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale

Ole Morten Ronning et al.

STROKE (2019)

Add to Collection

Letter Clinical Neurology

Recanalization before Thrombectomy in Tenecteplase vs. Alteplase-Treated Drip-and-Ship Patients

Pierre Seners et al.

JOURNAL OF STROKE (2019)

Add to Collection

Review Clinical Neurology

Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

William J. Powers et al.

STROKE (2019)

Add to Collection

Article Medicine, General & Internal

Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke

B. C. V. Campbell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials

Babikir Kheiri et al.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2018)

Add to Collection

Article Clinical Neurology

Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

Nicola Logallo et al.

LANCET NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis

William N. Whiteley et al.

LANCET NEUROLOGY (2016)

Add to Collection

Article Clinical Neurology

Alteplase versus tenecteplase for thrombolysis after Cross Mark ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study

Xuya Huang et al.

LANCET NEUROLOGY (2015)

Add to Collection

Article Clinical Neurology

Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke

Xuya Huang et al.

STROKE (2015)

Add to Collection

Article Clinical Neurology

Timing of Recanalization After Intravenous Thrombolysis and Functional Outcomes After Acute Ischemic Stroke

Leonard L. L. Yeo et al.

JAMA NEUROLOGY (2013)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Article Clinical Neurology

Low Rates of Acute Recanalization With Intravenous Recombinant Tissue Plasminogen Activator in Ischemic Stroke Real-World Experience and a Call for Action

Rohit Bhatia et al.

STROKE (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.